Table 4. Pathway analysis output of GO terms for genes present in all CNVs and the rare and novel CNVs of independent cases.
GO category | No. of reference genes in the category | No. of genes in the gene set and also in the category | Expected no. in the category | Ratio of enrichment | Raw P-value | P-value adjusted for multiple testing | |
---|---|---|---|---|---|---|---|
All CNVs | Molecular function – cyclic-nucleotide phosphodiesterase activity – GO:0004112 | 25 | 5 | 0.7 | 7.11 | 0.0006 | 0.04 |
All CNVs | Molecular function – acetylcholine binding – GO:0042166 | 13 | 4 | 0.37 | 10.94 | 0.0004 | 0.04 |
All CNVs | Molecular function – 3′,5′-cyclic-nucleotide phosphodiesterase activity – GO:0004114 | 24 | 5 | 0.68 | 7.41 | 0.0005 | 0.04 |
All CNVs | Cellular component – MHC protein complex – GO:0042611 | 38 | 6 | 1.09 | 5.53 | 0.0007 | 0.048 |
Rare and novel CNVs | Cellular component – proteasome activator complex – GO:0008537 | 3 | 2 | 0.02 | 84.21 | 0.0002 | 0.034 |
Rare and novel CNVs | Cellular component – nuclear inclusion body – GO:0042405 | 4 | 2 | 0.03 | 63.16 | 0.0004 | 0.034 |
Abbreviations: CNV, copy number variant; GO, gene ontology.
GO categories are listed that did not occur in population controls and survived multiple testing.